

# **Arthritis Research Foundation**

Financial Statements  
**March 31, 2024**



## Independent auditor's report

To the Board of Directors of Arthritis Research Foundation

---

### Our opinion

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Arthritis Research Foundation (the Foundation) as at March 31, 2024 and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

#### What we have audited

The Foundation's financial statements comprise:

- the statement of financial position as at March 31, 2024;
- the statement of operations and changes in fund balances for the year then ended;
- the statement of cash flows for the year then ended; and
- the notes to the financial statements, which include significant accounting policies and other explanatory information.

---

### Basis for opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Independence

We are independent of the Foundation in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada. We have fulfilled our other ethical responsibilities in accordance with these requirements.

---

### Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

PricewaterhouseCoopers LLP  
PwC Tower, 18 York Street, Suite 2500, Toronto, Ontario, Canada M5J 0B2  
T.: +1 416 863 1133, F.: +1 416 365 8215, Fax to mail: ca\_toronto\_18\_york\_fax@pwc.com



In preparing the financial statements, management is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Foundation's financial reporting process.

---

### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

*PricewaterhouseCoopers LLP*

Chartered Professional Accountants, Licensed Public Accountants

Toronto, Ontario  
June 20, 2024

**Arthritis Research Foundation**

## Statement of Financial Position

As at March 31, 2024

	2024 \$	2023 \$
<b>Assets</b>		
<b>Current assets</b>		
Cash	376,440	627,039
Accounts receivable	8,484	15,278
	<u>384,924</u>	<u>642,317</u>
<b>Investments</b> (note 3)	<u>26,642,605</u>	<u>23,955,186</u>
	<u>27,027,529</u>	<u>24,597,503</u>
<b>Liabilities</b>		
<b>Current liabilities</b>		
Accounts payable and accrued liabilities (note 4)	32,874	23,684
<b>Due to related entity</b> (note 4)	<u>94,682</u>	<u>92,766</u>
	<u>127,556</u>	<u>116,450</u>
<b>Fund Balances</b>		
<b>Endowment Fund</b> (note 5)	17,455,613	15,687,668
<b>Restricted Fund</b>	6,990,551	6,566,165
<b>General Fund</b>	<u>2,453,809</u>	<u>2,227,220</u>
	<u>26,899,973</u>	<u>24,481,053</u>
	<u>27,027,529</u>	<u>24,597,503</u>

**Approved by the Board of Directors***Richard Pilosof*\_\_\_\_\_  
Director*Andrew Phillips*\_\_\_\_\_  
Director

The accompanying notes are an integral part of these financial statements.

# Arthritis Research Foundation

## Statement of Operations and Changes in Fund Balances

For the year ended March 31, 2024

	Endowment Fund		Restricted Fund		General Fund		Total	
	2024 \$	2023 \$	2024 \$	2023 \$	2024 \$	2023 \$	2024 \$	2023 \$
<b>Revenue</b>								
Donations	5,000	5,000	9,648	74,033	86,065	187,357	100,713	266,390
Events	-	-	-	-	-	-	-	-
	5,000	5,000	9,648	74,033	86,065	187,357	100,713	266,390
<b>Investment income</b> (note 3)	1,762,945	(1,062,951)	627,582	669,920	264,407	199,405	2,654,934	(193,626)
	1,767,945	(1,057,951)	637,230	743,953	350,472	386,762	2,755,647	72,764
<b>Expenses</b>								
Fundraising	-	-	-	-	30,000	30,000	30,000	30,000
Administration	-	-	-	-	94,847	103,301	94,847	103,301
	-	-	-	-	124,847	133,301	124,847	133,301
<b>Surplus (deficiency) before grants</b>	1,767,945	(1,057,951)	637,230	743,953	225,625	253,461	2,630,800	(60,537)
<b>Grants</b> (note 6)	-	-	(211,880)	(1,380,848)	-	-	(211,880)	(1,380,848)
<b>Surplus (deficiency) for the year</b>	1,767,945	(1,057,951)	425,350	(636,895)	225,625	253,461	2,418,920	(1,441,385)
<b>Fund balances – Beginning of year</b>	15,687,668	16,745,619	6,566,165	7,210,963	2,227,220	1,965,856	24,481,053	25,922,438
<b>Interfund transfers</b>	-	-	(964)	(7,903)	964	7,903	-	-
<b>Fund balances – End of year</b>	17,455,613	15,687,668	6,990,551	6,566,165	2,453,809	2,227,220	26,899,973	24,481,053

The accompanying notes are an integral part of these financial statements.

**Arthritis Research Foundation**

## Statement of Cash Flows

For the year ended March 31, 2024

	2024 \$	2023 \$
<b>Cash provided by (used in)</b>		
<b>Operating activities</b>		
Surplus (deficiency) for the year	2,418,920	(1,441,385)
Items not involving cash		
Investment income reinvested	(1,227,254)	(1,355,430)
Change in fair value of investments (note 3)	(1,460,165)	1,522,187
Changes in non-cash working capital items		
Accounts receivable	6,794	(9,974)
Prepaid expenses	-	8,193
Accounts payable and accrued liabilities	9,190	(9,930)
Due to related entity	1,916	(32,838)
<b>Change in cash during the year</b>	(250,599)	(1,319,177)
<b>Cash – Beginning of year</b>	627,039	1,946,216
<b>Cash – End of year</b>	376,440	627,039

The accompanying notes are an integral part of these financial statements.

# Arthritis Research Foundation

## Notes to Financial Statements

March 31, 2024

---

### 1 Purpose of the organization

Arthritis Research Foundation (the Foundation) is incorporated without share capital under the laws of the Province of Ontario. The Foundation is a public foundation registered under the Income Tax Act (Canada) and, as such, is exempt from income taxes and is able to issue donation receipts for income tax purposes under registration number 11929 0773 RR0001. Its main purpose is to fundraise for The Arthritis & Autoimmunity Research Centre and related activities in the musculoskeletal and arthritis program at Sinai Health System.

### 2 Summary of significant accounting policies

The financial statements of the Foundation have been prepared in accordance with accounting standards for not-for-profit organizations (ASNPO). The following summary of significant accounting policies is set forth to facilitate the understanding of these financial statements.

#### Fund accounting

The Foundation follows the restricted fund method of accounting for contributions. The Foundation ensures, as part of its fiduciary responsibilities, that all funds received with a restricted purpose are expended for the purpose for which they were provided.

For financial reporting purposes, the accounts have been classified into the following funds:

- General Fund

The General Fund accounts for the Foundation's general fundraising, granting and administrative activities. The General Fund reports unrestricted resources available for immediate use.

- Restricted Fund

The Restricted Fund includes those funds where resources are to be used for an identified purpose as specified by the donor, as stipulated by the fundraising appeal or as determined by the Board of Directors.

Restricted donations, other than endowments, include a 10% allocation to the General Fund to highest priority needs.

- Endowment Fund

The Endowment Fund includes those funds where either donor or internal Board of Directors restrictions require the principal to be maintained by the Foundation for a specified period of time.



# **Arthritis Research Foundation**

## **Notes to Financial Statements**

**March 31, 2024**

---

### **Investments**

Publicly traded securities are valued based on the closing prices and pooled funds are valued based on reported unit values. Fixed income securities not publicly traded are valued based on cost plus accrued income. Transactions are recorded on a trade date basis and transaction costs are expensed as incurred.

### **Foreign currency translation**

Revenue and expenses denominated in foreign currencies are translated into Canadian dollars at the transaction date. Investments and other monetary items denominated in foreign currencies are translated at the year-end rate. Translation gains and losses are included in the statement of operations and changes in fund balances.

### **Revenue recognition**

The Foundation follows the restricted fund method of accounting for contributions, which include bequests and other donations. Bequests and other donations are recognized when received. Unrestricted contributions are recognized as revenue of the General Fund in the year received. Donor restricted contributions for specific purposes are recognized as revenue. Donor restricted contributions requiring the capital to be maintained permanently are recognized as revenue of the Endowment Fund.

Investment income consists of interest, dividends and change in fair value of investments, net of investment counsel and other investment expenses. Investment income earned on the Endowment Fund or Restricted Fund resources that must be spent on donor designated activities is recognized as revenue of the Restricted Fund. Investment income subject to donor restrictions stipulating that it be added to the endowment is recognized as revenue of the Endowment Fund. Unrestricted investment income earned on Endowment Fund, Restricted Fund and General Fund resources is recognized as revenue of the General Fund. Investment losses are allocated in a manner consistent with investment income.

The Foundation recognizes revenue from special events in the year in which the event occurs.

### **Pledges**

The Foundation records pledges as revenue when payment is received.

### **Contributed goods and services**

Contributed goods and services are not recognized in the financial statements.

# Arthritis Research Foundation

## Notes to Financial Statements

March 31, 2024

### Financial instruments and risk management

The Foundation initially recognizes financial instruments at fair value and subsequently measures them at each reporting date as follows:

Cash	amortized cost
Investments	fair value
Accounts receivable	amortized cost
Prepaid expenses	amortized cost
Accounts payable and accrued liabilities	amortized cost

Financial assets measured at amortized cost are assessed at each reporting date for indications of impairment. If such impairment exists, the asset shall be written down and the resulting impairment loss shall be recognized in the statement of operations and changes in fund balances for the year.

### Use of estimates

The preparation of financial statements in conformity with ASNPO requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual amounts could differ from those estimates.

### 3 Investments

	2024 \$	2023 \$
Canadian balanced pooled fund	24,451,015	21,848,852
Canadian fixed income pooled fund	2,191,590	2,106,334
	<u>26,642,605</u>	<u>23,955,186</u>

Investment income comprises the following:

	2024 \$	2023 \$
Interest income	714,051	697,761
Dividend income	542,193	687,286
Change in fair value of investments	1,460,165	(1,522,187)
	<u>2,716,409</u>	<u>(137,140)</u>
Investment income before fees	2,716,409	(137,140)
Investment fees	(61,475)	(56,486)
	<u>2,654,934</u>	<u>(193,626)</u>

# Arthritis Research Foundation

## Notes to Financial Statements

March 31, 2024

---

Fixed income bonds earn interest at a weighted average rate of 3.03% (2023 – 2.68%), maturing between January 2025 and May 2082.

### 4 Related party balances and transactions

The Foundation is managed by Sinai Health Foundation under a management services agreement. Under the agreement, Sinai Health Foundation provides certain services and pays certain expenses that are reimbursed at regular intervals throughout the year. As at March 31, 2024, the Foundation reimbursed \$100,000 (2023 – \$100,000) for such services. As at March 31, 2024, the total outstanding balance payable to Sinai Health Foundation is \$94,682 (2023 – \$92,766).

The Foundation provides financial resources by way of grants in support of the activities of Sinai Health System as approved by the Board of the Foundation.

### 5 Endowment Fund

Endowments consist of externally restricted donations received by the Foundation and internal resources transferred by the Board of Directors, in the exercise of its discretion. With respect to the latter case, the Board of Directors may have the right to subsequently decide to remove the designation. The endowment principal is required to be maintained intact over time, subject to the Foundation's endowment policy.

Investment income generated from endowments must be used in accordance with the various purposes established by the donors or the Board of Directors. The Foundation ensures, as part of its fiduciary responsibilities, that all funds received with a restricted purpose are expended for the purpose for which they were provided.

The Foundation's endowment policy was established by the Board of Directors with the objective of protecting the value of the endowments by limiting the amount of income made available for spending to the payout amount and requiring the reinvestment of income not made available for payout, with the objective of increasing the combined value of donated funds and cumulative investment returns at the rate of inflation or greater, over time (preservation of capital). The payout amount is calculated on the fund balance, and made available for spending restricted to the purposes set out in the donor agreement, if applicable, or as stipulated by the Board of Directors. The investment policy has established a minimum target rate of return objective as the sum of the payout rate and the inflation rate, with the aim of providing steady, predictable investment returns. The payout amount made available for spending is reviewed and set by the Board of Directors annually. For 2024, the payout amount was set at 5% (2023 – 5%), consisting of 4% recorded in the Restricted Fund and 1% recorded in the General Fund.

In any particular year, should net investment income be insufficient to satisfy the payout amount set by the Board of Directors, or if the investment return is negative, the payout amount is funded by the accumulated reinvested income in the Endowment Fund. In general, for individual endowment funds without sufficient accumulated reinvestment income, endowment capital is used in the current year. This amount is expected to be recovered by future net investment income.

# Arthritis Research Foundation

## Notes to Financial Statements

March 31, 2024

Major categories of restrictions on fund balances are as follows:

	2024 \$	2023 \$
Endowments, income from which must be used for research purposes	15,558,449	13,982,113
Endowments, income from which must be used for other restricted purposes	1,700,390	1,528,655
Endowments, income from which must be used as approved by the Board of Directors	196,774	176,900
	17,455,613	15,687,668

### 6 Grants

	2024 \$	2023 \$
Sinai Health System	150,000	100,000
University Health Network	51,880	1,280,848
Rheumatology Associates	10,000	-
	211,880	1,380,848

### 7 Interfund transfers

In fiscal 2024, the Foundation transferred \$964 (2023 – \$7,903) from the Restricted Fund to the General Fund to fund the payout amount on fund-restricted payments.

### 8 Financial instruments

The Foundation is exposed to various financial risks through its transactions in financial instruments.

#### Credit risk

The Foundation is exposed to credit risk in connection with its cash, short-term and fixed income investments because of the risk that one party to the financial instrument may cause a financial loss for the other party by failing to discharge an obligation. To manage this risk, the Foundation has an investment policy, which includes a target mix of investment types and concentration limits designed to achieve the optimum return within reasonable risk tolerances, and only does business with reputable financial institutions.

#### Interest rate risk

The Foundation is exposed to interest rate risk with respect to its investments in fixed income investments and a pooled fund that holds fixed income securities because the fair value will fluctuate due to changes in market interest rates.

#### Other price risk

The Foundation is exposed to other price risk through changes in market prices, other than changes arising from interest rate or currency risks, in connection with its investments in equity securities and pooled funds. To manage this risk, the Foundation invests in a target mix of investment types in accordance with its investment policy.